In prostate tumors with loss of PTEN, the high levels of CathepsinL promote the conversion of p200 CUX1 into its oncogenic isoform p110 CUX1, which in turn binds the promoter of ADAM17 and activates its transcription. ADAM17 then leads to the activation of Notch1 signaling which sustains tumor progression and may further reduce PTEN levels. This novel oncogenic network functions independently of PI3K/AKT pathway in the cells having loss of function of PTEN. This study may provide multiple entry points to design novel therapeutic intervention for PCa (e.g. CathepsinL inhibitors, ADAM17 inhibitors, -secretase inhibitors and AKT inhibitors). Fig. 1 on this page) 
Supplementary Figure 9 | Images of western blots in full (

